SGN-B6A

• Description :

  SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162) [1].

• UNSPSC :

  12352203

• Target :

  Antibody-Drug Conjugates (ADCs) ; Integrin

• Type :

  ADC Related

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cytoskeleton

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/sgn-b6a.html

• Purity :

  99.68

• Smiles :

  [SGN-B6A]

• Molecular Weight :

  150000 (average)

• References & Citations :

  [1]Lyon RP, et al., SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Mol Cancer Ther. 2023 Dec 1;22 (12) :1444-1453.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  -80°C, protect from light

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported